Emerging therapeutics for the treatment of diabetic nephropathy
作者： Jehrod Brenneman , Jon Hill , Steve Pullen
DOI: 10.1016/J.BMCL.2016.07.079
关键词:
摘要: Diabetic nephropathy (DN) is the most common pathology contributing to development of chronic kidney disease (CKD). DN caused by hypertension and unmitigated inflammation in diabetics, renders kidneys unable perform normally, leads renal fibrosis organ failure. The increasing global prevalence has been directly attributed rising incidences Type II diabetes, now largest non-communicable cause death worldwide. Despite high morbidity, successful new treatments for are lacking. This review seeks provide insight on emerging clinical candidates under investigation treatment DN.
elsevier.com
sci-hub.se 参考文章(85)
Shuei-Liong Lin, Yung-Ming Chen, Wen-Chih Chiang, Kwan-Dun Wu, Tun-Jun Tsai, Effect of Pentoxifylline in Addition to Losartan on Proteinuria and GFR in CKD: A 12-Month Randomized Trial American Journal of Kidney Diseases. ,vol. 52, pp. 464- 474 ,(2008) , 10.1053/J.AJKD.2008.05.012
Desiree Tampe, Michael Zeisberg, Potential approaches to reverse or repair renal fibrosis Nature Reviews Nephrology. ,vol. 10, pp. 226- 237 ,(2014) , 10.1038/NRNEPH.2014.14
Natesan Murugesan, Zhengxiang Gu, Leena Fadnis, John E Tellew, Rose Ann F Baska, Yifan Yang, Sophie M Beyer, Hossain Monshizadegan, Kenneth E Dickinson, Maria T Valentine, W Griffith Humphreys, Shih-Jung Lan, William R Ewing, Kenneth E Carlson, Mark C Kowala, Robert Zahler, John E Macor, None, Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2'-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics. Journal of Medicinal Chemistry. ,vol. 48, pp. 171- 179 ,(2005) , 10.1021/JM049548X
E. Jennifer Weil, Kevin V. Lemley, Clinton C. Mason, Berne Yee, Lois I. Jones, Kristina Blouch, Tracy Lovato, Meghan Richardson, Bryan D. Myers, Robert G. Nelson, Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy Kidney International. ,vol. 82, pp. 1010- 1017 ,(2012) , 10.1038/KI.2012.234
S. Giunti, G. H. Tesch, S. Pinach, D. J. Burt, M. E. Cooper, P. Cavallo-Perin, G. Camussi, G. Gruden, Monocyte chemoattractant protein-1 has prosclerotic effects both in a mouse model of experimental diabetes and in vitro in human mesangial cells. Diabetologia. ,vol. 51, pp. 198- 207 ,(2007) , 10.1007/S00125-007-0837-3
Giuseppe Remuzzi, Ariela Benigni, Fredric O Finkelstein, Jean-Pierre Grunfeld, Dominique Joly, Ivor Katz, Zhi-Hong Liu, Toshio Miyata, Norberto Perico, Bernardo Rodriguez-Iturbe, Luca Antiga, Franz Schaefer, Arrigo Schieppati, Robert W Schrier, Marcello Tonelli, Kidney failure: aims for the next 10 years and barriers to success The Lancet. ,vol. 382, pp. 353- 362 ,(2013) , 10.1016/S0140-6736(13)60438-9
Sergio Stefoni, Giuseppe Cianciolo, Olga Baraldi, Mario Iorio, Maria Laura Angelini, Emerging drugs for chronic kidney disease Expert Opinion on Emerging Drugs. ,vol. 19, pp. 183- 199 ,(2014) , 10.1517/14728214.2014.900044
Edmund J. Lewis, Lawrence G. Hunsicker, William R. Clarke, Tomas Berl, Marc A. Pohl, Julia B. Lewis, Eberhard Ritz, Robert C. Atkins, Richard Rohde, Itamar Raz, Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes The New England Journal of Medicine. ,vol. 345, pp. 851- 860 ,(2001) , 10.1056/NEJMOA011303
Hyun Mi Kang, Seon Ho Ahn, Peter Choi, Yi-An Ko, Seung Hyeok Han, Frank Chinga, Ae Seo Deok Park, Jianling Tao, Kumar Sharma, James Pullman, Erwin P Bottinger, Ira J Goldberg, Katalin Susztak, Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development Nature Medicine. ,vol. 21, pp. 37- 46 ,(2015) , 10.1038/NM.3762
Gentzon Hall, Janelle Rowell, Federica Farinelli, Rasheed A. Gbadegesin, Peter Lavin, Guanghong Wu, Alison Homstad, Andrew Malone, Thomas Lindsey, Ruiji Jiang, Robert Spurney, Gordon F. Tomaselli, David A. Kass, Michelle P. Winn, Phosphodiesterase 5 inhibition ameliorates angiontensin II-induced podocyte dysmotility via the protein kinase G-mediated downregulation of TRPC6 activity American Journal of Physiology-renal Physiology. ,vol. 306, ,(2014) , 10.1152/AJPRENAL.00212.2013